Related Experiment Video
Updated: Aug 7, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Control and Prevention of Invasive Pneumococcal Disease: A Current and Historical Perspective
Insights
Invasive pneumococcal disease (IPD) in children has decreased due to vaccines, but serotype replacement remains a concern. New vaccines offer broader coverage, but awareness of evolving IPD strategies is crucial for pediatricians.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Diseases
Background:
- Invasive pneumococcal disease (IPD) incidence in children has decreased with pneumococcal conjugate vaccines (PCVs).
- Serotype replacement, where non-vaccine serotypes increase after PCV introduction, has partially reversed gains from PCV7 and PCV13.
- Antibiotic resistance in emerging replacement serotypes poses a significant challenge.
Purpose of the Study:
- To review the current landscape of IPD prevention in children.
- To highlight the challenges posed by serotype replacement and antibiotic resistance.
- To inform pediatricians about evolving vaccine strategies and IPD management.
Main Methods:
- Review of literature on IPD epidemiology and vaccine impact.
- Analysis of trends in serotype distribution and antibiotic resistance.
- Discussion of current and upcoming PCV formulations (PCV15, PCV20) and polysaccharide vaccine recommendations.
Main Results:
- PCVs have significantly reduced IPD rates, but serotype replacement remains an issue.
- Emerging serotypes are often antibiotic-resistant, complicating treatment.
- Higher-valency vaccines (PCV15, PCV20) aim for broader coverage but may not cover all new serotypes.
Conclusions:
- Pediatricians need to stay informed about new vaccine strategies for IPD prevention.
- Awareness of IPD manifestations is essential for timely empirical therapy.
- Evolving vaccine recommendations for high-risk populations require careful consideration.
Abstract:
Although significant progress has been made in reducing the incidence of invasive pneumococcal disease (IPD) in children, IPD remains a continued threat. Since the introduction of pneumococcal conjugate vaccines (PCVs), rates of IPD and non-IPD have substantially decreased. However, serotype replacement reversed some of the benefits of PCV7 and, more recently, PCV13. Several replacement serotypes are antibiotic resistant, which is a cause of concern for providers. The introduction of the higher-valency conjugate vaccines PCV15 and PCV20 is expected to provide greater serotype coverage; unfortunately, these vaccines do not include some of the recently emerged serotypes. Recommendations for the use of the 23-valent polysaccharide vaccine in high-risk populations may be modified because of the effectiveness of the newer PCVs. Pediatricians must be aware of the new vaccine strategies for the prevention of IPD and the manifestations of IPD so that prompt empirical therapy can be initiated when treatment is required. [.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...